SCHEDULE: Sutro Biopharma: Affinity Asset Advisors Discloses 6.5% Stake

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,069,519 shares, representing 6.5% of Sutro Biopharma, Inc.'s common stock as of March 31, 2026.

Summary

• Affinity Asset Advisors, LLC, acting as the investment manager for Affinity Healthcare Fund, LP, and Michael Cho, the managing member of Affinity Asset Advisors, LLC, have disclosed their beneficial ownership of Sutro Biopharma, Inc. common stock.
• As of March 31, 2026, the total number of shares beneficially owned by Affinity Asset Advisors, LLC and Michael Cho is 1,069,519.
• This holding represents approximately 6.5% of the total outstanding common stock of Sutro Biopharma, Inc.
• The percentage is based on 16,567,762 shares of common stock outstanding as of March 31, 2026, as per the Issuer's Definitive Proxy Statement filed on April 22, 2026.
• The reporting persons have sole voting power and sole dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance information.

Positives

• Affinity Asset Advisors and Michael Cho hold a significant stake of 6.5% in Sutro Biopharma, Inc., indicating confidence in the company's prospects.
• The reporting persons have sole voting and dispositive power, suggesting direct control and influence over their investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders to report their holdings in publicly traded companies. This filing indicates a notable investment by Affinity Asset Advisors in Sutro Biopharma.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Affinity Asset Advisors may be viewed positively by other shareholders, potentially indicating confidence in the company's future. It also signals an active institutional investor in the company's stock.

Key Dates

Keywords

Sutro Biopharma, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing